DDRE-09. DEVELOPING IDO-PROTACS TO IMPROVE IMMUNOTHERAPEUTIC EFFICACY IN PATIENTS WITH GLIOBLASTOMA

INTRODUCTION: Indoleamine 2,3-dioxygenase 1 (IDO; IDO1) is a rate-limiting enzyme that metabolizes the essential amino acid tryptophan into kynurenine. Recent work by our group has revealed that IDO promotes tumor development and suppresses immune cell functions independent of its enzyme activity. M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Bollu, Lakshmi, Wainwright, Derek, Zhai, Lijie, Ladomersky, Erik, Lauing, Kristen, Bell, April, Schlitz, Gary
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Drug Discovery, Drug Resistance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651014/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.254
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados